Differential Residual Effects of Zaleplon and Zopiclone on Actual Driving: a Comparison with a Low Dose of Alcohol
The DOI matches its Crossref record.
Abstract
STUDY OBJECTIVES: To compare residual effects of zaleplon 10 mg, zopiclone 7.5 mg, and placebo, and a social dose of alcohol on car driving, memory, and psychomotor performance. DESIGN: Two-part placebo controlled, crossover study. Part 1 was single blind, Part 2 double blind. SETTING: University research institute. PARTICIPANTS: Thirty healthy volunteers (15 men and 15 women, mean age 32 +/- 7 years) INTERVENTIONS: In Part 1 alcohol and alcohol-placebo drinks were administered around noon. In Part 2 single oral doses of zaleplon 10 mg, zopiclone 7.5 mg and placebo were administered at bedtime. MEASUREMENT AND RESULTS: A highway driving test, laboratory tests of word learning, critical tracking and divided attention, and subjective assessments of sleep, mood, and effects of treatments on driving. Driving started 40 minutes after a second alcohol dose in Part 1, and 10 hours after drug intake in Part 2. The results demonstrated that alcohol, at average plasma concentrations of approximately 0.030 g/dl, significantly impaired performance in all tests. Zaleplon's residual effects did not differ significantly from those of placebo in any test. In contrast, zopiclone had significant residual effects on driving, divided attention, and memory. The magnitude of impairment in the driving test observed the morning after zopiclone 7.5 mg was twice that observed with alcohol. CONCLUSION: Zaleplon 10 mg has no residual effects on driving when taken at bedtime, 10 hours before driving. In contrast, zopiclone 7.5 mg can cause marked residual impairment. Patients should be advised to avoid driving the morning after zopiclone administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neurobehavioral Performance of Residents After Heavy Night Call vs After Alcohol Ingestion
Arnedt, J. T., Owens, J., Crouch, M., Stahl, J., & Carskadon, M. A. (2005) · JAMA · doi:10.1001/jama.294.9.1025 · Cited by 419
Ramaekers, J. G., Moeller, M. R., van Ruitenbeek, P., Theunissen, E. L., Schneider, E., & Kauert, G. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.015 · Cited by 290
Residual Effects of Hypnotics: Epidemiology and Clinical Implications
Vermeeren, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00003 · Cited by 277
Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011) · Drug Safety · doi:10.2165/11539050-000000000-00000 · Cited by 253
In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving
Gunja, N. (2013) · Journal of Medical Toxicology · doi:10.1007/s13181-013-0294-y · Cited by 177
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
“Racemic zopiclone’s utility may be limited by its potential for residual next-day effects and known associations with impaired driving ability (Bocca and Denise, 2000; Isawa et al., 2000; Vermeeren et al., 2002; Staner et al., 2005).”
BackgroundComparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98
Benefit-Risk Assessment of Zaleplon in the Treatment of Insomnia
Barbera, J., & Shapiro, C. (2005) · Drug Safety · doi:10.2165/00002018-200528040-00003 · Cited by 51
Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications
Greenblatt, D. J., & Zammit, G. K. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.741588 · Cited by 28
Metadata
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 25
- Issue
- 2
- Pages
- 224-31
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W1531560013
- Cited by
- 122
- References
- 0
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.